Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2052-2057, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Price, C. P.
Right arrow Articles by Darte, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Price, C. P.
Right arrow Articles by Darte, C.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1997;43:2052-2057.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Direct comparison of performance characteristics of two immunoassays for bone isoform of alkaline phosphatase in serum

Christopher P. Pricea, Thomas P. Milligan and Claude Darte

Department of Clinical Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Turner St., London E1 2AD, UK.
a Author for correspondence. Fax 44-171-377-1544; e-mail C.P.Price{at}mds.qmw.ac.uk

A clinical need exists for a sensitive and specific assay for the quantitation of the bone isoform of alkaline phosphatase in serum. The majority of methods do not meet this requirement; however, the recent development of immunoassays for this isoform may provide a solution. In a detailed evaluation of two immunoassays, we found a degree of imprecision that enables the discrimination of changes within the reference range. The cross-reactivity of the liver isoform was found to be between 7.1% and 12.7% when two different methods of assessment were used. The comparison of results with an electrophoretic procedure showed that the immunocapture method recovered less of the bone isoform in samples from children than in samples from patients with Paget disease; no such difference was found with the immunometric method. This suggests that the immunocapture antibody may discriminate between different bone isoforms in children whereas the immunometric assay does not.




The following articles in journals at HighWire Press have cited this article:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y.-C. Chung, C.-H. Ku, T.-Y. Chao, J.-C. Yu, M. M. Chen, and S.-H. Lee
Tartrate-resistant Acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 424 - 428.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. J. Janckila, K. Takahashi, S. Z. Sun, and L. T. Yam
Tartrate-resistant Acid Phosphatase Isoform 5b as Serum Marker for Osteoclastic Activity
Clin. Chem., January 1, 2001; 47(1): 74 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. L. Broyles, R. G. Nielsen, E. M. Bussett, W. D. Lu, I. A. Mizrahi, P. A. Nunnelly, T. A. Ngo, J. Noell, R. H. Christenson, and B. C. Kress
Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase
Clin. Chem., October 1, 1998; 44(10): 2139 - 2147.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.